Current therapeutics treating kidney disease patients have their limitations such as reduced sensitivity in patients. This article summarizes some novel drugs that have recently been approved or end-phase clinical trials for treating complicated kidney diseases. Tolvaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) Disease: Polycystic kidney disease (PKD) is the most common inherited genetic disease of the kidneys that is manifested with development and growth of multiple abnormal cysts in the kidneys. Two major types of PKD are: autosomal dominant and autosomal recessive.
Medicine: Tolvaptan is an antagonist to vasopressin receptor-2. It works in a selective and competitive manner. It’s currently being used to manage the condition of low blood sodium levels associated with cirrhosis, congestive heart failure, and syndrome of inappropriate antidiuretic hormone (SIADH).…
